TABLE 2

Crude odds ratios of increased use of inhaled corticosteroids in hormone therapy users

Timepoints (months)	Increase >0 µg OR (95% CI)	p-value	Increase >100 µg OR (95% CI)	p-value
Hormone therapy
3	1.00 (0.96–1.03)	0.9	1.05 (1.01–1.10)	0.012
6	1.04 (1.00–1.08)	0.032	1.09 (1.04–1.13)	<0.001
9	1.00 (0.97–1.04)	0.9	1.07 (1.03–1.12)	0.001
12	0.98 (0.94–1.01)	0.23	1.02 (0.98–1.06)	0.35
Hormone therapy by type
Systemic oestrogen
3	0.91 (0.83–0.99)	0.023	1.09 (1.00–1.20)	0.062
6	1.00 (0.92–1.08)	0.9	1.13 (1.03–1.24)	0.009
9	0.92 (0.84–1.00)	0.055	1.09 (0.99–1.19)	0.077
12	0.85 (0.78–0.93)	<0.001	1.02 (0.93–1.12)	0.7
Combination
3	0.94 (0.90–0.99)	0.027	1.05 (0.99–1.12)	0.08
6	0.95 (0.90–1.00)	0.058	1.06 (1.00–1.12)	0.050
9	0.99 (0.94–1.04)	0.6	1.09 (1.03–1.15)	0.004
12	0.92 (0.87–0.97)	0.002	1.01 (0.96–1.08)	0.6
Progestogens
3	0.82 (0.77–0.87)	<0.001	0.93 (0.87–1.00)	0.046
6	0.87 (0.82–0.93)	<0.001	0.97 (0.90–1.04)	0.37
9	0.86 (0.81–0.91)	<0.001	0.93 (0.87–1.00)	0.052
12	0.83 (0.78–0.88)	<0.001	0.89 (0.82–0.95)	0.001
Local oestrogen
3	0.94 (0.91–0.97)	<0.001	1.03 (0.99–1.07)	0.16
6	0.94 (0.91–0.97)	<0.001	1.00 (0.96–1.04)	0.99
9	0.94 (0.91–0.97)	<0.001	0.99 (0.95–1.03)	0.5
12	0.90 (0.87–0.94)	<0.001	0.96 (0.92–0.99)	0.025

Crude odds ratios of experiencing any increase or a large increase in mean daily dose of inhaled corticosteroids among the exposed women with asthma. Odds ratios are results from univariate logistic regression for each month. Hormone therapy is a binary exposure while subtype of hormone therapy is a factorised, five-level exposure. Odds for unexposed women is the reference odds for all categories.